LCQ908 + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease (NAFLD)
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Trial Timeline
Jun 1, 2013 → Sep 1, 2014
NCT ID
NCT01811472About LCQ908 + placebo
LCQ908 + placebo is a phase 2 stage product being developed by Novartis for Non-alcoholic Fatty Liver Disease (NAFLD). The current trial status is completed. This product is registered under clinical trial identifier NCT01811472. Target conditions include Non-alcoholic Fatty Liver Disease (NAFLD).
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease (NAFLD) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01811472 | Phase 2 | Completed |
| NCT01514461 | Phase 3 | Completed |
| NCT01387958 | Phase 2 | Terminated |
| NCT01146522 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease (NAFLD)